Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA

Autores: Abou-Alfa, G. K.; Chan, S. L.; Kudo, M.; Lau, G.; Kelley, R. K.; Furuse, J.; Sukeepaisarnjaroen, W.; Kang, Y. K.; Dao, T. V.; De Toni, E. N.; Rimassa, L.; Breder, V. V.; Vasilyev, A.; Heurgue, A.; Tam, V.; Mody, K.; Thungappa, S. C.; He, P.; Negro, A.; Sangro Gómez-Acebo, Bruno Carlos